Saitama, Japan

Shinya Onuma


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2005-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Shinya Onuma: Innovator in Ocular Therapeutics

Introduction

Shinya Onuma is a prominent inventor based in Saitama, Japan. He has made significant contributions to the field of ocular therapeutics, particularly through his innovative work on adenosine derivatives. With a total of 2 patents, Onuma's inventions focus on improving treatments for glaucoma and ocular hypertension.

Latest Patents

Onuma's latest patents include "Adenosine derivatives and use thereof - 2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5'-monophosphate, or salts thereof; and drugs containing the same as an active ingredient." These compounds exhibit excellent effects in lowering ocular tension, promoting blood flow in the retina, and protecting against optic nerve failure. Additionally, they are highly soluble in water, making them suitable for use as drugs for conditions such as glaucoma and ocular hypertension.

Career Highlights

Throughout his career, Onuma has worked with notable companies, including Toa Eiyo Ltd. and Yamasa Corporation. His experience in these organizations has contributed to his expertise in developing effective ocular treatments.

Collaborations

Onuma has collaborated with esteemed colleagues such as Takashi Konno and Kazuhiro Uemoto. These partnerships have further enhanced his research and development efforts in the field of ocular therapeutics.

Conclusion

Shinya Onuma's innovative work in the development of adenosine derivatives has the potential to significantly impact the treatment of ocular conditions. His contributions to the field exemplify the importance of research and innovation in improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…